BRPI0913410A2 - uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica - Google Patents
uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêuticaInfo
- Publication number
- BRPI0913410A2 BRPI0913410A2 BRPI0913410A BRPI0913410A BRPI0913410A2 BR PI0913410 A2 BRPI0913410 A2 BR PI0913410A2 BR PI0913410 A BRPI0913410 A BR PI0913410A BR PI0913410 A BRPI0913410 A BR PI0913410A BR PI0913410 A2 BRPI0913410 A2 BR PI0913410A2
- Authority
- BR
- Brazil
- Prior art keywords
- nanoparticle
- pharmaceutical composition
- aggregate
- nanoparticle aggregate
- pharmaceutical
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Radiation-Therapy Devices (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157686.0 | 2008-06-05 | ||
| EP08157686A EP2130553A1 (en) | 2008-06-05 | 2008-06-05 | Inorganic nanoparticles of high density to destroy cells in-vivo |
| US6020208P | 2008-06-10 | 2008-06-10 | |
| US61/060202 | 2008-06-10 | ||
| PCT/EP2009/056880 WO2009147214A2 (en) | 2008-06-05 | 2009-06-04 | Inorganic nanoparticles, preparation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0913410A2 true BRPI0913410A2 (pt) | 2015-11-24 |
| BRPI0913410B1 BRPI0913410B1 (pt) | 2021-09-21 |
Family
ID=39734334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0913410-7A BRPI0913410B1 (pt) | 2008-06-05 | 2009-06-04 | Uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8845507B2 (pt) |
| EP (4) | EP2130553A1 (pt) |
| JP (1) | JP5734181B2 (pt) |
| KR (1) | KR101639281B1 (pt) |
| CN (1) | CN102056628B (pt) |
| AU (1) | AU2009254550B2 (pt) |
| BR (1) | BRPI0913410B1 (pt) |
| CA (1) | CA2727576C (pt) |
| CY (2) | CY1118217T1 (pt) |
| DK (2) | DK3150227T3 (pt) |
| EA (1) | EA023012B1 (pt) |
| ES (2) | ES2702249T3 (pt) |
| HR (2) | HRP20161465T8 (pt) |
| HU (2) | HUE030669T2 (pt) |
| IL (1) | IL209625A (pt) |
| LT (2) | LT2300054T (pt) |
| MA (1) | MA32453B1 (pt) |
| MX (1) | MX2010013322A (pt) |
| NZ (1) | NZ589888A (pt) |
| PL (2) | PL3150227T3 (pt) |
| PT (2) | PT2300054T (pt) |
| SG (1) | SG10201405288WA (pt) |
| SI (2) | SI2300054T1 (pt) |
| TR (1) | TR201819077T4 (pt) |
| WO (1) | WO2009147214A2 (pt) |
| ZA (1) | ZA201100082B (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070164238A1 (en) * | 2003-02-24 | 2007-07-19 | Pomper Mark E | Mobile radiation treatment vehicle and method |
| US8657354B2 (en) | 2006-05-19 | 2014-02-25 | Breya, Llc. | Mobile radiation therapy |
| US8459714B2 (en) | 2006-05-19 | 2013-06-11 | Breya, Llc. | Mobile radiation therapy |
| US9399075B2 (en) | 2008-12-29 | 2016-07-26 | General Electric Company | Nanoparticle contrast agents for diagnostic imaging |
| US8728440B2 (en) | 2012-08-23 | 2014-05-20 | General Electric Company | Nanoparticulate compositions for diagnostic imaging |
| US9585840B1 (en) | 2009-07-10 | 2017-03-07 | University Of Central Florida Research Foundation, Inc. | Redox active cerium oxide nanoparticles and associated methods |
| EP2275137A1 (en) | 2009-07-10 | 2011-01-19 | Nanobiotix | Metallic nanoparticles, preparation and uses thereof |
| CN102870235B (zh) * | 2009-11-10 | 2016-11-23 | 免疫之光有限责任公司 | 用于从包括用于上变频的射频、微波能量和磁感应源的各种能量源产生发射光的上下变频系统 |
| WO2011133228A2 (en) * | 2010-04-23 | 2011-10-27 | Pixelligent Technologies, Llc | Synthesis, capping and dispersion of nanocrystals |
| EP3190083B1 (en) | 2010-10-27 | 2020-08-26 | Pixelligent Technologies, LLC | Synthesis, capping and dispersion of nanocrystals |
| US9359689B2 (en) | 2011-10-26 | 2016-06-07 | Pixelligent Technologies, Llc | Synthesis, capping and dispersion of nanocrystals |
| EA029635B1 (ru) | 2011-12-16 | 2018-04-30 | Нанобиотикс | Применение наночастицы, включающей металлический материал, покрытый материалом оксида гафния, в онкологии и композиция, ее содержащая |
| AU2013274093A1 (en) * | 2012-06-14 | 2014-12-18 | Bioventures, Llc | Compositions and methods for non-invasive detection and treatment of hypoxic cells in vivo |
| US8821838B2 (en) | 2012-08-23 | 2014-09-02 | General Electric Company | Nanoparticulate compositions for diagnostic imaging |
| AR094577A1 (es) * | 2013-01-25 | 2015-08-12 | Nanobiotix | Composiciones para el tratamiento de cáncer, preparación y usos de las mismas |
| KR101999421B1 (ko) * | 2013-02-19 | 2019-07-11 | 내셔날 헬스 리서치 인스티튜트 | 항암 화학치료제를 위한 케이지된 백금 나노클러스터 |
| WO2014191569A1 (en) | 2013-05-30 | 2014-12-04 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| EA201690050A1 (ru) * | 2013-06-20 | 2016-05-31 | Нанобиотикс | Композиции и способы для применения в медицинской диагностике |
| JP6671292B2 (ja) * | 2013-12-16 | 2020-03-25 | ジェネンテック, インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
| EP3229776B1 (en) * | 2014-11-25 | 2023-06-28 | Curadigm Sas | Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof |
| SG11201704143YA (en) | 2014-11-25 | 2017-06-29 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| EP3223796B1 (en) | 2014-11-25 | 2021-07-21 | Curadigm Sas | Pharmaceutical compositions, preparation and uses thereof |
| ES2774365T3 (es) | 2014-11-25 | 2020-07-20 | Curadigm Sas | Composición farmacéutica, preparación y usos de la misma |
| UA123665C2 (uk) | 2014-11-25 | 2021-05-12 | Кюрадігм Сас | Фармацевтична композиція, її одержання і застосування |
| US20180008733A1 (en) * | 2015-01-08 | 2018-01-11 | Purdue Research Foundation | Non-toxic formulations of radio-luminescent nanoparticles for use as cancer radio-sensitizing agents |
| UA124572C2 (uk) * | 2015-05-28 | 2021-10-13 | Нанобіотікс | Наночастинки для застосування як терапевтичної вакцини |
| US11389536B2 (en) | 2015-07-17 | 2022-07-19 | BioCurity Pharmaceuticals Inc. | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| CN109010828B (zh) * | 2018-10-12 | 2020-10-20 | 中国科学院高能物理研究所 | 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途 |
| CN109616308B (zh) * | 2018-11-07 | 2020-09-04 | 湖北第二师范学院 | 一种球形纳米氧化铱dna提取磁性粉末及其生产方法 |
| CN109771645B (zh) * | 2019-03-07 | 2021-08-24 | 广西师范大学 | 一种二氧化钌复合卵清蛋白纳米材料的制备及其应用 |
| KR20230038659A (ko) * | 2020-05-26 | 2023-03-21 | 나노비오띡스 | 나노 입자, 전리 방사선 및 그의 혁신적인 치료용 조합 |
| CN116507366A (zh) * | 2020-11-05 | 2023-07-28 | 纳米生物技术公司 | 用于治疗癌症的纳米颗粒组合物 |
| US20240000940A1 (en) * | 2020-12-01 | 2024-01-04 | Nanobiotix S.A. | Porous, high-z and carbon-free particles as radioenhancers |
| AR131316A1 (es) | 2022-12-12 | 2025-03-05 | Nanobiotix S A | Novedosas nanopartículas de óxido de metal y composiciones de las mismas para uso como radiopotenciadores o para visualizar tejido biológico |
| EP4595983A1 (en) | 2024-02-05 | 2025-08-06 | BXTA Nanotherapy Limited | Nanoparticles functionalised with a stabilising agent and a targeting agent |
| WO2026074471A1 (en) * | 2024-10-02 | 2026-04-09 | Janssen Pharmaceutica Nv | Combination therapies with hafnium oxide nanoparticles and pd-l1 antibodies for use in the treatment of non small cell lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6287526A (ja) * | 1985-10-11 | 1987-04-22 | Akira Fujishima | 抗腫瘍剤 |
| US6645464B1 (en) | 1998-07-30 | 2003-11-11 | James F. Hainfeld | Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy |
| EP1696957A2 (en) | 2003-12-17 | 2006-09-06 | Philips Intellectual Property & Standards GmbH | Radiation therapy and medical imaging using uv emitting nanoparticles |
| FR2869803B1 (fr) | 2004-05-10 | 2006-07-28 | Nanobiotix Sarl | Particules activables, preparation et utilisations |
| US20070092927A1 (en) * | 2005-06-13 | 2007-04-26 | University Of Dayton | Photocatalytic particles with directed and controlled redox activity |
| JP2007075696A (ja) * | 2005-09-13 | 2007-03-29 | Mitsubishi Materials Corp | 多孔質光触媒膜 |
| US20090191128A1 (en) * | 2006-07-10 | 2009-07-30 | Koninklijke Philips Electronics N.V. | Core-shell nanoparticles for thearapy and imaging purposes |
| EP1920784A1 (en) * | 2006-11-13 | 2008-05-14 | Koninklijke Philips Electronics N.V. | Radiation sensitizers in ionizing radiation therapy and imaging |
-
2008
- 2008-06-05 EP EP08157686A patent/EP2130553A1/en not_active Withdrawn
-
2009
- 2009-06-04 LT LTEP09757595.5T patent/LT2300054T/lt unknown
- 2009-06-04 SG SG10201405288WA patent/SG10201405288WA/en unknown
- 2009-06-04 LT LTEP16187263.5T patent/LT3150227T/lt unknown
- 2009-06-04 CN CN2009801211030A patent/CN102056628B/zh active Active
- 2009-06-04 PL PL16187263T patent/PL3150227T3/pl unknown
- 2009-06-04 SI SI200931555A patent/SI2300054T1/sl unknown
- 2009-06-04 PT PT97575955T patent/PT2300054T/pt unknown
- 2009-06-04 AU AU2009254550A patent/AU2009254550B2/en active Active
- 2009-06-04 HR HRP20161465TT patent/HRP20161465T8/hr unknown
- 2009-06-04 DK DK16187263.5T patent/DK3150227T3/en active
- 2009-06-04 WO PCT/EP2009/056880 patent/WO2009147214A2/en not_active Ceased
- 2009-06-04 CA CA2727576A patent/CA2727576C/en active Active
- 2009-06-04 PL PL09757595T patent/PL2300054T3/pl unknown
- 2009-06-04 ES ES16187263T patent/ES2702249T3/es active Active
- 2009-06-04 EP EP09757595.5A patent/EP2300054B1/en active Active
- 2009-06-04 DK DK09757595.5T patent/DK2300054T3/en active
- 2009-06-04 EP EP18203014.8A patent/EP3461502A1/en active Pending
- 2009-06-04 EP EP16187263.5A patent/EP3150227B1/en active Active
- 2009-06-04 HU HUE09757595A patent/HUE030669T2/en unknown
- 2009-06-04 EA EA201071429A patent/EA023012B1/ru unknown
- 2009-06-04 MX MX2010013322A patent/MX2010013322A/es active IP Right Grant
- 2009-06-04 NZ NZ589888A patent/NZ589888A/en unknown
- 2009-06-04 BR BRPI0913410-7A patent/BRPI0913410B1/pt active IP Right Grant
- 2009-06-04 US US12/994,162 patent/US8845507B2/en active Active
- 2009-06-04 SI SI200931905T patent/SI3150227T1/sl unknown
- 2009-06-04 JP JP2011512129A patent/JP5734181B2/ja active Active
- 2009-06-04 ES ES09757595.5T patent/ES2602048T3/es active Active
- 2009-06-04 TR TR2018/19077T patent/TR201819077T4/tr unknown
- 2009-06-04 KR KR1020117000259A patent/KR101639281B1/ko active Active
- 2009-06-04 PT PT16187263T patent/PT3150227T/pt unknown
- 2009-06-04 HU HUE16187263A patent/HUE040247T2/hu unknown
-
2010
- 2010-11-29 IL IL209625A patent/IL209625A/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00082A patent/ZA201100082B/en unknown
- 2011-01-04 MA MA33490A patent/MA32453B1/fr unknown
-
2016
- 2016-11-01 CY CY20161101109T patent/CY1118217T1/el unknown
-
2018
- 2018-11-27 HR HRP20181993TT patent/HRP20181993T1/hr unknown
- 2018-12-19 CY CY181101377T patent/CY1121078T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0913410A2 (pt) | uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica | |
| BRPI0917001A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica | |
| BRPI0917315A2 (pt) | anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica | |
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| BRPI0908792A2 (pt) | Composição, e, uso de uma combinação | |
| BRPI0912717A2 (pt) | Composição farmacêutica, e, uso de 5-azacitidina | |
| BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0813770A2 (pt) | Composição, e, uso de uma composição | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BRPI1008039A2 (pt) | composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica | |
| BR112013001571A2 (pt) | composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40 | |
| BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
| BRPI1005931A2 (pt) | associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica | |
| BRPI0816350A2 (pt) | Composições orais, produtos e métodos de uso | |
| BRPI0914793A2 (pt) | Composição, e, uso de uma composição | |
| BRPI1013421A2 (pt) | composição parasticida tópica, e, uso de uma composição | |
| BRPI0905715A2 (pt) | Composição farmacêutica e kit de componentes | |
| BRPI1014316A2 (pt) | composição, e, uso de uma composição | |
| BRPI0906253A2 (pt) | Composição de dentifrício, e, uso de uma composição | |
| BRPI0918206A2 (pt) | derivados de animoéster e composição medicinal destes | |
| BRPI1006953A2 (pt) | composição farmacêutica, e, uso de uma composição | |
| BRPI0915473A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0920355A2 (pt) | composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |